Mobile

A phase III, open, multi-centre, controlled study to evaluate the long-term antibody persistence at 2 years, 3 years and 4 years after a single dose of GlaxoSmithKline (GSK) Biologicals’ meningococca...

Update Il y a 4 ans
Reference: EUCTR2008-003824-51

A phase III, open, multi-centre, controlled study to evaluate the long-term antibody persistence at 2 years, 3 years and 4 years after a single dose of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroup A, C, W-135, Y- tetanus toxoid conjugate (MenACWY-TT) vaccine versus one dose of Meningitec™ administered in healthy 12 through 23-month old children who were primed in study MenACWY-TT-039 (109670) and to evaluate the immunogenicity and safety of a booster dose of the same meningococcal conjugate vaccine as given in the primary study, 4 years after priming

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Immunogenicity Persistence At 24, 36, and 48 months after primary vaccination of toddlers with MenACWY-TT or Meningitec •To evaluate the persistence of meningococcal antibodies in terms of the percentage of subjects with rSBA antibody titres ≥ 1:8 for each of the four serogroups.

Inclusion criteria

  • Healthy male and female children who completed the primary immunisation study MenACWY-TT-039 (109670) and were 12 to 23 months of age at the time of primary vaccination

Links